Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer
Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer
复制标题
前列腺癌患者内分泌治疗反应的代谢组学评估
DOI：
10.1016/j.ejphar.2014.01.048
复制
发表时间：
2014-04-15
影响因子：
5
通讯作者：
Sun, Yinghao
中科院分区：
文献类型：
--
作者：
Huang, Gang;Liu, Xinru;Sun, Yinghao
及时评估前列腺癌（PCa）患者对内分泌治疗的反应可以优化治疗方案并改善长期预后。我们使用液相色谱-质谱（LC-MS）代谢组学技术，以确定血清生物标志物的疾病进展和治疗benefit.The平均血清水平的七种代谢物，包括脱氧胆酸（DCA），甘氨鹅脱氧胆酸（GCDC），L-色氨酸，二十二碳五烯酸（DPA），花生四烯酸，脱氧胞苷三磷酸，和吡啶啉，未经治疗的前列腺癌患者和健康对照组之间的显着差异。在至少2年未发生去势抵抗性前列腺癌（CRPC）的患者（良好应答者）中，这些代谢物水平在内分泌治疗期间恢复至接近健康对照水平。相比之下，在1年内发生CRPC的患者（反应差的患者）中，代谢物水平仍然异常。这些生物标志物中的三种（DCA. GCDC和DPA）主要参与胆固醇代谢，强调了胆固醇升高对PCa进展的重要性。这些代谢物可作为预测性生物标志物，用于评估前列腺癌患者对内分泌治疗的治疗反应。(C)2014 Elsevier By. All rights reserved.
Timely evaluation of the response to endocrine therapy in patients with prostate cancer (PCa) may optimize treatment regimens and improve long-term prognosis. We used the liquid chromatography mass spectrometry (LC-MS) metabolomic technique to identify serum biomarkers indicative of disease progression and therapeutic benefit.The mean serum levels of seven metabolites, including deoxycholic acid (DCA), glycochenodeoxycholate (GCDC), L-tryptophan, docosapentaenoic acid (DPA), arachidonic acid, deoxycytidine triphosphate, and pyridinoline, differed significantly between untreated PCa patients and healthy controls. In patients who did not develop castration resistant prostate cancer (CRPC) for at least 2 years (good responders), these metabolite levels reverted to near healthy control levels during endocrine therapy. In contrast, the metabolite levels remained abnormal in patients who developed CRPC within 1 year (poorly responsive patients). Three of these biomarkers (DCA. GCDC, and DPA) are mainly involved in cholesterol metabolism, underscoring the importance of elevated cholesterol to PCa progression. These metabolites may serve as predictive biomarkers for assessing the therapeutic response of PCa patients to endocrine therapy. (C) 2014 Elsevier By. All rights reserved.